For Immediate Release

March 24, 2026

 

CYNAERA Founder Cynthia Adinig’s Research Selected for Presentation at CRISPRMED26

 

Washington, D.C. – March 24, 2026 – Cynthia Adinig, founder of CYNAERA, has been selected to present her research at the 2026 CRISPR Medicine Conference (CRISPRMED26), marking a significant expansion of her work into gene editing and precision medicine.

 

The selected research, “CRISPR Remission: A Flare-Aware Gene Editing Pathway Engine for Immune-Volatile Chronic Disease,” introduces a new approach to gene editing for conditions such as Long COVID, ME/CFS, and other infection-associated chronic conditions.  CRISPR Remission™ is designed to account for biological instability by integrating flare-aware immune logic, environmental and physiological timing, and real-time patient terrain modeling.

 

“This was never some distant pipe dream for me,” said Adinig. “I began this work because I wanted to build a path toward treatment, remission, and ultimately cure, not only for myself, but for my family and for the many others living with these conditions.”

 

Adinig’s work draws from years of research, federal policy engagement, and large-scale patient interaction across Long COVID and related chronic illness communities. She previously served in an appointed role with the Office of Long COVID at the U.S. Department of Health and Human Services. It also builds on earlier published work, including her 2022 Milken Institute essay, “Unexpected Outcomes: How the Pandemic Transformed Post-viral Illness in the US.”

 

CRISPR Remission™ is part of CYNAERA’s broader modular intelligence infrastructure platform, which develops AI-powered systems for predictive modeling, therapeutic strategy, clinical trial simulation, and multi-condition disease mapping across healthcare, government, and research sectors. Her broader CYNAERA platform also includes CYNAERA REPURPOSED™, an AI-driven fast-track drug repurposing framework for infection-associated chronic conditions, reflecting her focus on both near-term treatment access and longer-term cure pathways.

 

Based on CYNAERA’s internal analysis, this development has implications for more than 50 immune-volatile, inflammatory, and infection-associated chronic conditions. This work also supports CYNAERA’s women-centered initiative focused on accelerating treatment, remission, and cure pathways across hormone-linked immune disruption and related women’s health conditions.

 

She hopes this recognition helps bring much-needed interest from pharmaceutical companies and philanthropists to Long COVID, ME/CFS, Lyme disease, and other historically neglected conditions. Many of these illnesses disproportionately affect women, and the work may also hold relevance for growing investment in women’s health, including menopause and other hormone-linked conditions shaped by immune instability, inflammatory burden, and delayed diagnosis.

 

This announcement comes during Long COVID Awareness Month, Women’s History Month, and ME/CFS Advocacy Week, highlighting the growing role of patient-led innovation in shaping the future of biomedical research.

 

The full CRISPR Remission™ white paper is available on the CYNAERA website.

 

About CYNAERA
CYNAERA is a modular intelligence infrastructure platform designed for enterprise integration across healthcare, government, climate resilience, and population risk systems. The platform combines predictive systems modeling, AI-driven analytics, and multi-sector data integration to support decision-making in complex, dynamic environments.

 

Press Contact:
Email: cynthia@cynaera.com

 

Related Links:

https://www.cynaera.com/post/crispr-remission

https://www.cynaera.com/project-eve

​